Keyphrases
Phase II Trial
100%
Chronic Lymphocytic Leukemia
100%
Ibrutinib
100%
Venetoclax
100%
Minimal Residual Disease
66%
Bone Marrow
55%
Complete Remission
44%
Monotherapy
33%
Disease Remission
33%
Tumor Protein p53 (TP53)
22%
Combination Therapy
22%
Previously Untreated Patients
22%
Immunoglobulin Heavy Chain Gene
22%
Bruton Tyrosine Kinase Inhibitor
22%
Del17p
22%
Bcl-2 Inhibitor
22%
International Workshop
22%
Fluorescence in Situ Hybridization
11%
High Risk
11%
Overall Survival
11%
Gene mutation
11%
Remission
11%
Best Response
11%
Progression-free Survival
11%
TP53 mutation
11%
Combination Treatment
11%
Combined Treatment
11%
Disease Rate
11%
Single Center
11%
Mutation Status
11%
Trial Registration
11%
3-cycle
11%
High-risk Disease
11%
Richter Transformation
11%
Intent-to-treat Analysis
11%
Anti-CD20 Antibody
11%
Multicolor Flow Cytometry
11%
Leukemia Progression
11%
Intervention Therapy
11%
Treatment Indication
11%
Non-randomized Trial
11%
Del(11q)
11%
Oral Targeted Therapy
11%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
100%
Ibrutinib
100%
Venetoclax
100%
Minimal Residual Disease
66%
Monotherapy
33%
Spontaneous Remission
33%
Combination Therapy
22%
Immunoglobulin Heavy Chain
22%
Bruton Tyrosine Kinase Inhibitor
22%
Gene Mutation
11%
Flow Cytometry
11%
Diseases
11%
Targeted Therapy
11%
Overall Survival
11%
CD20
11%
Monoclonal Antibody
11%
Progression Free Survival
11%
Fluorescence in Situ Hybridization
11%
Intention-to-Treat Analysis
11%
Richter's Transformation
11%
Treatment Indication
11%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Ibrutinib
100%
Venetoclax
100%
Remission
88%
Minimal Residual Disease
66%
Monotherapy
33%
Combination Therapy
22%
Immunoglobulin Heavy Chain
22%
Bruton Tyrosine Kinase Inhibitor
22%
Diseases
11%
Overall Survival
11%
Monoclonal Antibody
11%
Progression Free Survival
11%
Flow Cytometry
11%
Preclinical Study
11%